Harness Therapeutics

Neuronal inclusions in Huntington’s disease
#Genetic diseases #Harness Therapeutics #Huntington's disease #Neuroscience

Harness Therapeutics nominates drug candidate for Huntington’s

Harness Therapeutics has announced the nomination of HRN001 as its lead drug candidate for Huntington’s disease (HD).  The company has also formed a clinical advisory board to support the programme’s advancement towards clinical evaluation.  Despite significant advances in understanding HD disease biology, there are currently… Read More

#News